Wednesday, September 13, 2017 3:44:09 PM
I skimmed through most of it just to get an idea of what it entails, and it looks like they found a legitimate method to regenerate brain tissue. The risk here (as with all biotechs in the early stages) lies in how much this patent is worth. And of course, the FDA will have the final say on whether or not this technology can be commercialized.
This statistic in particular stood out to me:
If Ariel's tech can reduce costs by even 50%, the patent would be worth $382.5M (assuming the Company is fully diluted and that is their sole asset.) Pretty interesting to think about...
It also looks like the CEO owns an investment firm called CubeSquare LLC. So if we see lots of his funds filtering into the stock, it will be an indication that future FDA trials show promise.
Thanks for your DD. Looking forward to reading more about the patent.
Recent QRON News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 09:16:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM